NASDAQ$NPCE
Neuropace Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
NeuroPace's revenue increased significantly, driven by initial implant sales.
NeuroPace reported a strong second quarter with a 65% increase in total revenue, driven by a 100% increase in initial implant revenue. The company is progressing with its plans to expand the indication of its RNS System and is on track to begin enrolling patients before the end of the year.
- Total revenue reached $12.6 million, a 65% increase year-over-year.
- Initial implant revenue was $9.2 million, a 100% increase year-over-year.
- Gross margin improved to 74.1% compared to 71.0% in the prior year period.
- Net loss was $8.5 million, slightly better than the $8.8 million loss in the prior year period.
Headline financials
Revenue & EPS history
Neuropace · Revenue · Quarterly
$12.6M
Revenue by segment
Neuropace · $1.6M total across 1 segment · Q4 2022
- DIXI Medical$1.6M—100.0%
Forward guidance
Management continues to take a measured approach given the uncertainty surrounding COVID-19. The company reiterates full year 2021 guidance.
Tailwinds
- Total revenue of approximately $47 million, representing growth of 14% compared to prior year.
- Initial implant revenue of approximately $36 million, representing growth of 29% compared to prior year.
- Initial implant revenue guidance of $36 million includes minimal clinical study revenue.
Headwinds
- Uncertainty surrounding COVID-19, including the risk posed by new variants and the potential impact on hospital, physician and patient behavior.
- Replacement implant revenue of approximately $11 million, representing a decline of 16% compared to prior year.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2021
-0.7%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-0.1%
Avg return
30 days after
50%
12 / 24 earnings
Positive
+37.4%
Q3 2025
Best reaction
-40.1%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.6% | -1.8% | — | |
| Q4 2025 | +1.1% | +1.6% | +5.9% | |
| Q3 2025 | +37.4% | +43.1% | +74.5% | |
| Q1 2025 | +21.6% | +31.3% | -14.5% | |
| Q4 2024 | -2.4% | -15.8% | +2.6% | |
| Q3 2024 | +25.7% | +23.4% | +49.9% | |
| Q2 2024 | -1.9% | -0.4% | +4.8% | |
| Q1 2024 | -40.1% | -35.9% | -51.4% | |
| Q4 2023 | +0.8% | +2.5% | -8.4% | |
| Q3 2023 | -1.4% | +9.5% | +14.6% | |
| Q2 2023 | +9.8% | +9.8% | +103.4% | |
| Q1 2023 | +1.9% | -3.5% | -15.4% | |
| Q4 2022 | -13.3% | -7.8% | -1.9% | |
| Q3 2022 | -9.9% | -17.6% | -29.6% | |
| Q2 2022 | -3.5% | -10.2% | -26.6% | |
| Q1 2022 | +1.2% | -3.6% | -3.8% | |
| Q4 2021 | -0.9% | -7.7% | -1.2% | |
| Q3 2020 | -15.2% | -22.2% | -47.7% | |
| Q3 2021 | -15.2% | -22.2% | -47.7% | |
| Q2 2021 | -7.6% | -10.7% | -8.0% | |
| Q2 2020 | -7.6% | -10.7% | -8.0% | |
| Q1 2020 | +0.8% | +8.7% | +2.2% | |
| Q1 2021 | +0.8% | +8.7% | +2.2% | |
| Q4 2020 | +0.8% | +8.7% | +2.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro